Drug Profile


Alternative Names: OLT-1177

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Olatec Industries
  • Developer Olatec Therapeutics
  • Class Analgesics; Anti-inflammatories
  • Mechanism of Action Inflammasome inhibitors; Interleukin 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout; Musculoskeletal pain
  • Preclinical Myocardial reperfusion injury

Most Recent Events

  • 11 Nov 2017 Preclinical trials in Myocardial reperfusion injury in USA
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Musculoskeletal-pain(In volunteers) in USA (PO, Capsule)
  • 14 Jun 2017 Preclinical data in gout presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top